The numerically higher rate of congenital anomalies observed with risankizumab did not reach statistical significance and showed no pattern suggestive of causality; nonetheless, these findings warrant monitoring in larger cohorts.
1
—
—
The numerically higher rate of congenital anomalies observed with risankizumab did not reach statistical significance and showed no pattern suggestive of causality; nonetheless, these findings warrant monitoring in larger cohorts.